OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Denise Yardley on PI3K Inhibitors

January 29th 2015

Denise Yardley, MD, senior investigator, breast cancer research, Sarah Cannon Research Institute discusses the phase II FERGI study and how it can be applied to more than just breast cancer.

Dr. Kluger on Toxicity of Nivolumab/ Ipilimumab for Advanced Melanoma

January 29th 2015

Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, talks about the toxicity of nivolumab and ipilimumab for the treatment of patients with advanced melanoma.

Dr. Belani on PD-1 Inhibitors for Non-Small Cell Lung Cancer

January 28th 2015

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses the benefits of immunotherapy for lung cancer.

Dr. DeVita Discusses the 10th Edition of Cancer: Principles and Practice of Oncology

January 28th 2015

Giant of Cancer Care, Vincent T. DeVita, Jr, MD, from the Yale School of Medicine, talks about the 10th Edition of Cancer: Principles and Practice of Oncology, an internationally acclaimed book geared toward practicing oncologists.

Dr. Adelson on Bortezomib plus Fulvestrant for HR+ Breast Cancer

January 27th 2015

Kerin Adelson, MD, Assistant Professor of Medicine, Hematology, and Medical Oncology at the Icahn School of Medicine at Mount Sinai, explains the results of a phase II clinical trial comparing fulvestrant alone with bortezomib plus fulvestrant for the treatment of hormone receptor-positive metastatic breast cancer.

Dr. David Rimm on Immunofluorescence for HER2 Identification

January 26th 2015

David Rimm MD, PhD, professor of pathology and medicine, director of pathology tissue services, Yale University School of Medicine, explains the benefits of quantitativecfor the measurement of HER2 proteins.

Joan Lunden and Dr Patrick Borgen Discuss Imaging and Genetic Testing in Breast Cancer

January 23rd 2015

Joan Lunden talks about imaging technology and genetic testing for the early detection of breast cancer with Roy Firestone and Patrick I. Borgen, MD, in advance of her keynote address at the 32nd Miami Breast Cancer Conference.

Dr. Tward on Abbreviated Course ADT for Prostate Cancer

January 23rd 2015

Jonathan Tward, MD, PhD, Associate Professor of Radiation Oncology at the Huntsman Cancer Institute, discusses abbreviated course androgen-deprivation therapy (ADT) for prostate cancer treatment.

Dr. Lawrence Mayer on CPX-351 for Acute Myeloid Leukemia

January 23rd 2015

Lawrence Mayer, PhD, president, founder and chief scientific officer of Celator Pharmaceuticals, explains the technology behind CPX-351, a liposomal formulation of cytarabine and daunorubicin. CPX-351 was recently granted Fast Track Designation by the FDA for the treatment of elderly patients with relapsed acute myeloid leukemia (AML).

Joan Lunden Discusses Her TNBC Diagnosis With Roy Firestone

January 22nd 2015

Joan Lunden discusses the diagnostic approach that led to the early detection of triple-negative breast cancer, which was undetected by mammogram and 3D mammogram but was detected with ultrasound.

Dr. Edith Perez on Etirinotecan Pegol for HER2-Negative Breast Cancer

January 22nd 2015

Edith A. Perez, MD, the deputy director at large for the Mayo Clinic Cancer Center, discusses the BEACON trial.

Dr. Scott Rowley on Allogeneic Stem Cell Transplant

January 21st 2015

Scott Rowley, MD, the Chief of John Theurer Cancer Center's Blood and Marrow Stem Cell Transplantation Division, discusses the challenges of allogeneic stem cell transplant.

Dr. Stewart on the Safety Profile of Carfilzomib in Multiple Myeloma Patients

January 20th 2015

A. Keith Stewart, MBChB, from the Mayo Clinic, discusses the safety profile of carfilzomib (Kyprolis) when used in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.

Dr. Donna McNamara on PARP Inhibitors for Ovarian Cancer Treatment

January 20th 2015

Donna McNamara, MD, Co-Chief of the Gynecologic Oncology Division and Medical Oncologist for the Breast Oncology Division at the John Theurer Cancer Center, talks about the benefits of PARP inhibitors for women with BRCA1 or BRCA2-mutated, platinum-sensitive ovarian cancer.

Dr. Muro on Pembrolizumab for Gastric Cancer

January 19th 2015

Kei Muro, MD, of the Aichi Cancer Center Hospital in Nagoya, Japan, discusses updated findings from the KEYNOTE-012 study, which looked at pembrolizumab for the treatment if several types of cancer.

Dr. Laura Dawson on HCC Challenges

January 19th 2015

Laura Dawson, MD, Princess Margaret Hospital, University of Toronto, talks about the challenges in treating hepatocellular carcinoma (HCC).

Dr. Alvarnas on Stem Cell Transplant for HIV-Associated Lymphoma

January 15th 2015

Joseph Alvarnas, MD, the director of Medical Quality at City of Hope National Medical Center, discusses autologous hematopoietic stem cell transplantation (AHCT) for patients with HIV-associated lymphoma.

Dr. Goy Discusses the Impact of the Roche/Foundation Medicine Partnership

January 14th 2015

Andre Goy, MD, MS chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses the impact of Roche's recent acquisition of the molecular testing company Foundation Medicine.

Dr. Wolchok on Remaining Questions Regarding Immunotherapies in Melanoma

January 13th 2015

Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses remaining questions regarding immunotherapies for the treatment of melanoma.

Dr. Cookson on Ideal Bladder Cancer Biomarkers

January 13th 2015

No one biomarker is effective for all types of bladder cancer, says Michael Cookson, MD, a professor and chairman of the Department of Urology at the University of Oklahoma College of Medicine.